Pharmaron Beijing Co (HKSE:03759) Beta: 2.2039 (As of Jul. 06, 2026)


HKSE:03759 Pharmaron Beijing Co Ltd HKSE:03759
95 GF Score
Price HK$20.58
GF Value HK$22.58
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Beta?

Pharmaron Beijing Co HKSE:03759 +5.43% 95 Beta is 2.2039 as of Jul. 06, 2026. GuruFocus rates HKSE:03759 with a GF Score™ of 95/100 and a GF Value™ of HK$22.58 (Fairly Valued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-06), Pharmaron Beijing Co's Beta is 2.2039.


Pharmaron Beijing Co  (HKSE:03759) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Pharmaron Beijing Co Beta Related Terms


Pharmaron Beijing Co Beta Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Beta Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.90 1.89 2.23 2.18

Pharmaron Beijing Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 2.20 2.30 2.18 2.23

HKSE:03759 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Pharmaron Beijing Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Beta distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Beta falls into.


HKSE:03759
95GF Score
Pharmaron Beijing Co Ltd HKSE:03759
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.2039 mean?
Pharmaron Beijing Co (HKSE:03759) has a Beta of 2.2039 as of Jul. 06, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Beta too high?
Pharmaron Beijing Co's current Beta is 2.2039. Overall, Pharmaron Beijing Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Beta compare to VRTX and REGN?
Pharmaron Beijing Co's Beta of 2.2039 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Beta is 2.2039. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Fairly Valued. The stock's GF Value™ is HK$22.58, compared to a current price of HK$20.58 — trading 8.9% below its estimated fair value. The current Beta is 2.2039. Pharmaron Beijing Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current Beta is 2.2039 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be undervalued. The current stock price of HK$20.58 is trading 8.9% below its estimated GF Value™ of HK$22.58. GuruFocus considers Pharmaron Beijing Co to be Fairly Valued.

Key valuation signals for HKSE:03759:

  • Beta: 2.2039
  • GF Value™: HK$22.58 vs. price of HK$20.58 (8.9% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmaron Beijing Co Business Description

Other Exchanges 17Q1:Germany300759:China
Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
95GF Score

Get the complete analysis for HKSE:03759

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$20.58
Price
HK$22.58
GF Value